| Identification | Back Directory | [Name]
(2E)-3-[4-(benzyloxy)phenyl]-1-(thiophen-2-yl)prop-2-en-1-one | [CAS]
1666119-75-0 | [Synonyms]
NSC321039
hMAO-B-IN-4
(2E)-3-[4-(benzyloxy)phenyl]-1-(thiophen-2-yl)prop-2-en-1-one
2-Propen-1-one, 3-[4-(phenylmethoxy)phenyl]-1-(2-thienyl)-, (2E)- | [Molecular Formula]
C20H16O2S | [MDL Number]
MFCD01893914 | [MOL File]
1666119-75-0.mol | [Molecular Weight]
320.4 |
| Hazard Information | Back Directory | [Uses]
hMAO-B-IN-4 (compound B10) is a selective, reversible and blood–brain barrier (BBB) penetrable human monoamine oxidase-B (hMAO-B) inhibitor with an IC50 value and a Ki value of 0.067 and 0.03 μM, respectively. hMAO-B-IN-4 inhibits hMAO-A with an IC50 value of 33.82 μM. hMAO-B-IN-4 can be used for Alzheimer’s disease (AD) and Parkinson’s disease (PD) research[1]. | [References]
[1] Sudevan ST, et al. Introduction of benzyloxy pharmacophore into aryl/heteroaryl chalcone motifs as a new class of monoamine oxidase B inhibitors. Sci Rep. 2022 Dec 27;12(1):22404. DOI:10.1038/s41598-022-26929-x |
|
| Company Name: |
EvoBlocks, Ltd.
|
| Tel: |
+36 (20) 5757-305 |
| Website: |
www.evoblocks.com |
|